EPZ5676: Potent and Selective DOT1L Inhibitor for Advanced Epigenetic Cancer Research

Executive Summary: EPZ5676 is a highly selective DOT1L inhibitor with an IC₅₀ of 0.8 nM and a Ki of 80 pM, making it one of the most potent SAM-competitive inhibitors for DOT1L histone methyltransferase studied to date (APExBIO). The compound demonstrates >37,000-fold selectivity against other methyltransferases and is validated for use in biochemical and cellular assays. EPZ5676 induces potent cytotoxicity in MLL-rearranged acute leukemia cell lines by blocking H3K79 methylation (Anbazhagan et al., 2024). In vivo studies reveal complete tumor regression in MV4-11 xenograft rat models without significant toxicity. The compound's reproducibility and specificity establish its utility in advanced epigenetic and cancer research workflows.

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is the sole histone methyltransferase responsible for methylating H3K79, a key epigenetic mark associated with active gene transcription. Aberrant activity of DOT1L is implicated in acute leukemias with mixed lineage leukemia (MLL) gene rearrangements. MLL fusion proteins recruit DOT1L to aberrant genomic loci, driving oncogenic gene expression and leukemogenesis (Anbazhagan et al., 2024). Selective inhibition of DOT1L disrupts this process, leading to the downregulation of MLL-fusion target genes and induction of cytotoxicity in cancerous cells. EPZ5676 was developed to exploit this vulnerability, offering a targeted strategy for MLL-rearranged leukemia treatment. The importance of precise epigenetic modulation in cancer is further supported by recent research into the interplay of histone modifications and chromatin state regulation (see comparative workflows).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a SAM-competitive inhibitor that binds to the S-adenosyl methionine (SAM) binding pocket of DOT1L. This interaction induces a conformational change, opening a hydrophobic pocket beyond the amino acid portion of SAM and preventing methyl transfer to histone H3K79. EPZ5676 displays an IC₅₀ of 0.8 nM and a Ki of 80 pM in DOT1L enzyme inhibition assays (APExBIO). Selectivity profiling shows >37,000-fold preference for DOT1L over other methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMT family members, SETD7, SMYD2/3, and WHSC1/1L1. In cellular models, EPZ5676 inhibits H3K79 methylation, leading to reduced expression of MLL-fusion oncogenes and marked arrest of leukemia cell proliferation (for integrative perspectives).

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L enzymatic activity with an IC₅₀ of 0.8 nM and Ki of 80 pM in vitro (APExBIO).
• Demonstrates >37,000-fold selectivity versus CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1 (APExBIO).
• Induces potent cytotoxicity in MLL-rearranged MV4-11 leukemia cells with an IC₅₀ of 3.5 nM after 4–7 days of exposure (Anbazhagan et al., 2024).
• In vivo, 35–70 mg/kg/day intravenous administration for 21 days causes complete regression of MV4-11 xenografts in nude rats with no significant toxicity or weight loss (APExBIO).
• No significant inhibition of non-DOT1L methyltransferases at <1 μM concentrations (scenario-based analysis).
• Enables robust reduction of H3K79 methylation and downregulation of MLL-fusion target gene expression in leukemia models (applied epigenetics).

Applications, Limits & Misconceptions

EPZ5676 is primarily employed in biochemical enzyme inhibition assays and cell proliferation studies targeting MLL-rearranged leukemia. It is a validated tool for dissecting the role of DOT1L-mediated H3K79 methylation in oncogenesis, enabling translational research and preclinical therapeutic evaluation. Its specificity and robust in vivo activity have made it a benchmark for selective epigenetic modulation in cancer.

For further details on troubleshooting and assay design, see DOT1L Inhibitor EPZ-5676 (SKU A4166): Practical Solutions, which this article extends by providing updated selectivity and in vivo efficacy data.

Common Pitfalls or Misconceptions

• EPZ5676 is not effective against solid tumors lacking MLL rearrangements; its primary efficacy is observed in MLL-rearranged leukemia models.
• The compound is insoluble in water; attempts to use aqueous stock solutions lead to precipitation and loss of activity.
• Non-specific cytotoxic effects are minimal below 1 μM; higher concentrations may yield off-target effects.
• Long-term storage of solutions, even at low temperatures, can result in degradation; only short-term aliquots in DMSO are recommended (see product handling).
• DOT1L-independent mechanisms of leukemogenesis are not targeted by EPZ5676; resistance may develop in genetically heterogeneous models.

Workflow Integration & Parameters

EPZ5676 is supplied as a solid compound (molecular weight: 562.71 Da) and is soluble at ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol (with ultrasonic assistance). It is insoluble in water. For biochemical assays, prepare fresh DMSO stock solutions and store aliquots at −20°C. In cell-based assays, MV4-11 cells respond to EPZ5676 at an IC₅₀ of 3.5 nM after 4–7 days of treatment. In vivo, use 35–70 mg/kg/day via intravenous injection for 21 days in rodent xenograft models. Avoid repeated freeze-thaw cycles and long-term storage of working solutions. The DOT1L inhibitor EPZ-5676 kit from APExBIO is validated for both enzyme and proliferation assays.

Conclusion & Outlook

EPZ5676 has set a new standard for potent and selective DOT1L inhibition, enabling precise dissection of H3K79 methylation dynamics in MLL-rearranged leukemia models. Its nanomolar potency, high selectivity, and robust in vivo efficacy support its continued use in advanced epigenetic research and preclinical drug discovery. Future innovation may include combinatorial strategies and broader application in other epigenetic contexts, as explored in related translational research, which this article clarifies by emphasizing DOT1L specificity and cytotoxic benchmarks.